Compare TG Therapeutics Inc (TGTX) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Unity Software Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Unity Software Inc trades at $42.65 (market cap $18.81B). The key difference: Unity Software Inc is far larger — about 2.2× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| TGTX | U | |
|---|---|---|
Market Cap | $8.53B | $18.81B |
Sector | Health | Technology |
52-Week High | $59.06 | $49.47 |
52-Week Low | $26.94 | $17.13 |
Enterprise Value | $8.74B | $18.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Unity Software (U) trades at $42.75, up 2.62% with bullish technical signals and strong analyst support. The company shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though still reporting negative net income. Recent Q2 2026 earnings beat expectations, while institutional activity shows mixed positioning with some major funds increasing stakes. Technical indicators suggest bullish momentum with support at $41 and resistance at $44.
The outlook remains cautiously optimistic with 81% analyst buy ratings and $47.45 price target, representing 11% upside. Key opportunities include Vector platform growth and margin expansion, while risks center on sustained profitability challenges and competitive pressures in the gaming/ad tech space. Execution on strategic initiatives will be critical for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
